UC Study Links Some Antibody‑Drug Conjugates to High Rates of Severe Neutropenia

Overview

• The peer‑reviewed analysis used University of California Health records from 2012–2024 and reviewed 10 FDA‑approved antibody‑drug conjugates in 3,511 patients across six UC medical centers.
• The study found substantial rates of severe neutropenia and related complications, including febrile neutropenia, hospital admission, and intensive care use, linked to some but not all ADCs.
• Risk varied widely by specific drug and by patient factors, with higher complication rates in people who had anemia or immunodeficiency disorders.
• Authors urged clinicians to increase vigilance and consider earlier blood‑count monitoring and preventive measures for higher‑risk patients, a recommendation publicized on June 2 and June 3 following the paper’s publication.
• The researchers emphasize that this observational UC‑system study shows associations rather than proven causation and that large health‑system datasets can reveal safety signals that warrant further research and may change supportive‑care practices.